Ekso Bionics®’ EksoGT Exoskeleton Adopted in Singapore for Groundbreaking Clinical Study

May 06, 2019 - 06:53
Ekso Bionics®’ EksoGT Exoskeleton Adopted in Singapore for Groundbreaking Clinical Study

RICHMOND, CA - Media OutReach - May 6, 2019 - Ekso Bionics Holdings,Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medicaland industrial use, today announced that the National University Health System(NUHS) in Singapore has adopted three EksoGT exoskeletons for a groundbreakingclinical study. NUHS is one of the first national health systems in Asia tostudy how advanced exoskeleton technology can improve mobility andrehabilitation outcomes, and the first to study it acrossthe entire continuum of care.



Photograph courtesy of Ekso Bionics

 

The ImprovingMobility via Exoskeletons (iMOVE) program, supported byTemasek Foundation and Trailblazer Foundation Limited, will study patientoutcomes and assess the viability and potential for scaling-up the use ofrobotic exoskeletons across the continuum of rehabilitation care from hospitalto community.  The study will focus on patientssuffering from stroke and spinal cord injuries, especially for the elderly.  The three EksoGT devices will be used atmultiple NUHS partner sites including Alexandra Hospital, NTUC Health, StLuke's Eldercare, St Luke's Hospital, and Stroke Support Station.


The iMOVE program was inaugurated today by Mr. Chan Heng Kee, PermanentSecretary of Ministry of Health, together with Professor John Wong Eu Li, ChiefExecutive of National University Hospital System and Mr. Richard Magnus,Chairman of Temasek Foundation. 

 

"We are delighted to be part of a program thatwill facilitate greater treatment accessibility in Singapore. Globally 15 million people suffer from a stroke every year; Asia ismore than half the world's population with a rapidly aging population in manycountries.  With aging, mobility becomesa big challenge.  The core mission of Ekso is to help peoplere-learn how to stand and walk after a stroke or spinal cord injury. We wantthe EksoGT systems to be widely accessible to people who never thought theycould walk or stand up again," commented Ms. LimChwee Foon, President, Asia Pacific, Ekso Bionics. "This will serve as a solidplatform for our growth in Asia."

 

With Ekso Bionics' recent expansion plan inAsia Pacific, EksoGTs are now deployed in Singapore, Hong Kong, and Australia. Todate, EksoGT has helped patients take more than 100 million steps in over 260 rehabilitationinstitutions around the world.

About EksoGT

EksoGT is the first exoskeleton cleared by theFDA for use with stroke and spinal cord injuries from L5 to C7. In Europe, theCE-Mark cleared EksoGT allows us to work with patients impacted by allneurological conditions and lower limb weakness. The EksoGT with SmartAssistsoftware is the only exoskeleton available for rehabilitation institutions thatcan provide adaptive amounts of power to either side of a patient's body,challenging the patient as they progress through their continuum of care. Thesuit's patented technology provides the ability to mobilize patients earlier,more frequently, and with a greater number of high intensity steps. To date, thisdevice has helped patients take 100 million steps in over 260 rehabilitationinstitutions around the world.

About Ekso Bionics®

Ekso Bionics® is a leadingdeveloper of exoskeleton solutions that amplify human potential by supportingor enhancing strength, endurance and mobility across medical and industrialapplications. Founded in 2005, the company continues to build upon itsunparalleled expertise to design some of the most cutting-edge, innovativewearable robots available on the market. Ekso Bionics is the only exoskeletoncompany to offer technologies that range from helping those with paralysis tostand up and walk, to enhancing human capabilities on job sites across theglobe. The company is headquartered in the Bay Area and is listed on the NasdaqCapital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Forward-Looking Statements

Any statements contained in this press release that do not describehistorical facts may constitute forward-looking statements. Forward-lookingstatements may include, without limitation, statements regarding (i) the plansand objectives of management for future operations, including plans orobjectives relating to the design, development and commercialization of humanexoskeletons, including the iMOVE program and study results, (ii) estimates,projections or other future statements regarding financial performance, resultsand condition, capital expenditures, capital structure or other financial items,including statements relating to growth in Asia, and (iii) the assumptionsunderlying or relating to any statement described in points (i) or (ii) above.Such forward-looking statements are not meant to predict or guarantee actualresults, performance, events or circumstances and may not be realized becausethey are based upon the Company's current projections, plans, objectives,beliefs, expectations, estimates and assumptions and are subject to a number ofrisks and uncertainties and other influences, many of which the Company has nocontrol over. Actual results and the timing of certain events and circumstancesmay differ materially from those described by the forward-looking statements asa result of these risks and uncertainties. Factors that may influence orcontribute to the inaccuracy of the forward-looking statements or cause actualresults to differ materially from expected or desired results may include,without limitation, the Company's inability to obtain adequate financing tofund the Company's operations and necessary to develop or enhance ourtechnology, the significant length of time and resources associated with thedevelopment of the Company's products, the Company's failure to achieve broadmarket acceptance of the Company's products, the failure of our sales andmarketing organization or partners to market our products effectively, adverseresults in future clinical studies of the Company's medical device products,the failure to obtain or maintain patent protection for the Company'stechnology, failure to obtain or maintain regulatory approval to market theCompany's medical devices, lack of product diversification, existing orincreased competition, and the Company's failure to implement the Company'sbusiness plans or strategies. These and other factors are identified anddescribed in more detail in the Company's filings with the SEC. To learn moreabout Ekso Bionics please visit us at www.eksobionics.com. The Company does notundertake to update these forward-looking statements. 

E-paper